Navigation Links
New FDLI Monograph on Federal Price Reporting Requirements Provides Essential Guidance on Commercial Strategy, Compliance Issues
Date:7/17/2009

WASHINGTON, July 17 /PRNewswire-USNewswire/ -- The Food and Drug Law Institute has published the first monograph in its landmark Monograph Series -- Price Reporting Basics under Medicaid, Medicare and the PHS340(b) Program: Planning for Both Compliance and Commercial Success.

Written by Alice Valder Curran, a partner at Hogan & Hartson, LLP, in Washington, D.C., and two associates at the firm, Emily S. Gebba and Sarah H. Zinn, the monograph concisely summarizes the price calculation and reporting obligations under the Medicaid Drug Rebate Program, the Public Health Service (PHS) Drug Pricing Program, and the Medicare Average Sales Price reporting requirement.

Pharmaceutical or biologics manufacturers who seek federal coverage of their products under the Medicaid and Medicare Part B programs must agree to participate in certain federal price reporting and discount programs. Those price reporting obligations often are misperceived as a back-room accounting function with perhaps some associated compliance obligations but still little relevance to daily commercial operations and strategy. That's not the case. These price reporting and discount programs instead have the potential to significantly affect the commercial pricing and discount strategy for almost any product, according to the monograph.

In addition, ongoing federal enforcement efforts and recent, comprehensive rulemaking should make federal price reporting obligations a central compliance and commercial strategic focus at manufacturers of all sizes. This monograph provides lawyers and business leaders with a user-friendly overview of each price point's calculation mechanics as well as how common commercial arrangements can affect those calculations.

Finally, the monograph includes two sample charts for manufacturers to use to start tracking important data and documenting their own price calculation methodologies.

FDLI's Monograph Series is designed to provide in-depth, practical analysis and guidance for attorneys on complex issues in food and drug law. New monographs are published every two months and are available for purchase, both as a part of a subscription product and individually. Monographs are available only as downloadable PDF files from FDLI's website (www.fdli.org).

Founded in 1949, FDLI publishes the award-winning, peer-reviewed Food and Drug Law Journal; the bimonthly magazine Update; FDA Directory; and dozens of books and publications for attorneys, regulatory affairs practitioners, scientists, health care professionals, government employees and marketers in the food and drug field.


'/>"/>
SOURCE Food and Drug Law Institute
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. USP announces 11 new proposed monographs for dietary supplements
2. USP announces revised glycerin monograph
3. US Pharmacopeia announces revised heparin monographs and reference standards
4. ABC Releases Monograph on Scientific Research of POM Wonderful(R) Pomegranate Juice
5. MDMA Names New Director of Federal Affairs
6. Federal research plan to determine nanotech risks fails to deliver
7. Federal Employee Program Maintains Low Health Premiums In 2008
8. AMERIGROUP Contracts with Federal Government to Offer Medicare Advantage Health Plans in Seven States
9. SNM applauds NAS study showing need to restore federal nuclear medicine research funding
10. ACM Helps Medicaid Programs Comply With Federal Deficit Reduction Act Mandates
11. Boise(R) BEWARE(TM) Meets New Federal Guidelines Set Forth by Medicaid
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... February 23, 2017 , ... Healthcare Research & Analytics® (HRA®) ... fight against cancer, has produced a seminal study that asked cancer survivors and ... findings in a webinar, Defining Compassionate Care Through the Voices of Patients and ...
(Date:2/23/2017)... ... ... CALNOC, the nation’s first and only nursing quality indicators database today announced ... and Collaboration – in Seattle, WA on October 23, 2017. , Dr. Gary Kaplan ... Seattle since 2000. In addition to his role at Virginia Mason, Dr. Kaplan also ...
(Date:2/23/2017)... ... ... HealthPostures, the desk for standing designer headquartered in Prior Lake, Minnesota has announced ... and Garden Show which is being held February 24 through 26 and March 3 ... Convention Center. , From its broad line of sit stand desk solutions, HealthPostures ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... a new healthcare contact center in Georgia, PENETRON Specialty Products (PSP) provided the ... largest healthcare systems recently invested $51 million to purchase and renovate the 185,000 ...
(Date:2/22/2017)... ... 2017 , ... Stem cell therapy has made significant innovations ... cutting edge, in fact, the U.S. Food and Drug Administration (FDA) has yet ... outcomes in certain clinical stem cell procedures have shown that this revolutionary field ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... 23, 2017 LG Innotek today announced that the company ... As its sterilization performance is 1.5 times higher than the competitor,s ... rays in the range of 200 -- 280nm, allowing it to be ... destroying their DNA. LG Innotek,s product emits UV in the range ... Until ...
(Date:2/23/2017)... 23, 2017 ML Capital Group, Inc. (USOTC: ... Colorado Highlife Tours , a Colorado -based ... with Puration, Inc. (USOTC: PURA) to enter Colorado,s ... The Colorado Highlife Tours acquisition announced today is intended to accelerate ... ...
(Date:2/23/2017)... , Feb. 23, 2017 Provectus Biopharmaceuticals, ... "Company"), a clinical-stage oncology and dermatology biopharmaceutical company, today ... and Dominic Rodrigues as special advisers to ... Rodrigues will advise the board on financial and corporate ... received an investment commitment of up to $2.5 million ...
Breaking Medicine Technology: